Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 2/20 | 0.62 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2696317 | 0.90 | MEN1 (0.65) | CRHBPCRHR2L3MBTL1MAPK1KMT2A | |
| SCHEMBL4863822 | 0.87 | L3MBTL1 (0.53) | CRHBPCRHR2L3MBTL1MAPK1KMT2A | |
| SCHEMBL4865019 | 0.81 | KMT2A (0.51) | CRHBPCRHR2L3MBTL1MAPK1KMT2A | |
| SCHEMBL5467064 | 0.80 | CRHBP (0.62) | CRHBPCRHR2L3MBTL1MAPK1KMT2A | |
| SCHEMBL31011828 | 0.80 | KMT2A (0.67) | L3MBTL1KMT2AMEN1ATMTSHR | |
| SCHEMBL10879279 | 0.79 | GAA (0.50) | CRHBPCRHR2KMT2AMEN1TSHR | |
| SCHEMBL8814333 | 0.79 | KMT2A (0.46) | CRHBPCRHR2L3MBTL1MAPK1KMT2A | |
| SCHEMBL19214081 | 0.79 | L3MBTL1 (0.55) | CRHBPCRHR2L3MBTL1KMT2AMEN1 | |
| SCHEMBL7334845 | 0.78 | CRHBP (0.47) | CRHBPCRHR2L3MBTL1MAPK1KMT2A | |
| SCHEMBL2985901 | 0.77 | KMT2A (0.62) | L3MBTL1MAPK1KMT2AMEN1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | CRHBP 784/4885CRHR2 32/4885L3MBTL1 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.